Connection

LAWRENCE DONEHOWER to Tumor Suppressor Protein p53

This is a "connection" page, showing publications LAWRENCE DONEHOWER has written about Tumor Suppressor Protein p53.
  1. Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas. Cell Rep. 2019 07 30; 28(5):1370-1384.e5.
    View in: PubMed
    Score: 0.476
  2. Phosphatases reverse p53-mediated cell cycle checkpoints. Proc Natl Acad Sci U S A. 2014 May 20; 111(20):7172-3.
    View in: PubMed
    Score: 0.331
  3. Insights into wild-type and mutant p53 functions provided by genetically engineered mice. Hum Mutat. 2014 Jun; 35(6):715-27.
    View in: PubMed
    Score: 0.326
  4. Effects of TP53 mutational status on gene expression patterns across 10 human cancer types. J Pathol. 2014 Apr; 232(5):522-33.
    View in: PubMed
    Score: 0.325
  5. Wild-type p53-induced phosphatase 1 dephosphorylates histone variant gamma-H2AX and suppresses DNA double strand break repair. J Biol Chem. 2010 Apr 23; 285(17):12935-47.
    View in: PubMed
    Score: 0.246
  6. Using mice to examine p53 functions in cancer, aging, and longevity. Cold Spring Harb Perspect Biol. 2009 Dec; 1(6):a001081.
    View in: PubMed
    Score: 0.242
  7. 20 years studying p53 functions in genetically engineered mice. Nat Rev Cancer. 2009 11; 9(11):831-41.
    View in: PubMed
    Score: 0.241
  8. Altered senescence, apoptosis, and DNA damage response in a mutant p53 model of accelerated aging. Mech Ageing Dev. 2009 Apr; 130(4):262-71.
    View in: PubMed
    Score: 0.233
  9. MMP13, Birc2 (cIAP1), and Birc3 (cIAP2), amplified on chromosome 9, collaborate with p53 deficiency in mouse osteosarcoma progression. Cancer Res. 2009 Mar 15; 69(6):2559-67.
    View in: PubMed
    Score: 0.232
  10. Longevity regulation in flies: a role for p53. Aging (Albany NY). 2009 Jan 10; 1(1):6-8.
    View in: PubMed
    Score: 0.229
  11. The Wip1 phosphatase and Mdm2: cracking the "Wip" on p53 stability. Cell Cycle. 2008 Jan 15; 7(2):164-8.
    View in: PubMed
    Score: 0.214
  12. Aging-associated truncated form of p53 interacts with wild-type p53 and alters p53 stability, localization, and activity. Mech Ageing Dev. 2007 Nov-Dec; 128(11-12):717-30.
    View in: PubMed
    Score: 0.211
  13. Altered mammary gland development in the p53+/m mouse, a model of accelerated aging. Dev Biol. 2008 Jan 01; 313(1):130-41.
    View in: PubMed
    Score: 0.210
  14. The Wip1 Phosphatase acts as a gatekeeper in the p53-Mdm2 autoregulatory loop. Cancer Cell. 2007 Oct; 12(4):342-54.
    View in: PubMed
    Score: 0.210
  15. Tumor suppressor dosage regulates stem cell dynamics during aging. Cell Cycle. 2007 Jan 01; 6(1):52-5.
    View in: PubMed
    Score: 0.199
  16. The impact of altered p53 dosage on hematopoietic stem cell dynamics during aging. Blood. 2007 Feb 15; 109(4):1736-42.
    View in: PubMed
    Score: 0.196
  17. PPM1D dephosphorylates Chk1 and p53 and abrogates cell cycle checkpoints. Genes Dev. 2005 May 15; 19(10):1162-74.
    View in: PubMed
    Score: 0.177
  18. Homeostatic regulation of base excision repair by a p53-induced phosphatase: linking stress response pathways with DNA repair proteins. Cell Cycle. 2004 Nov; 3(11):1363-6.
    View in: PubMed
    Score: 0.172
  19. Cooperativity of p19ARF, Mdm2, and p53 in murine tumorigenesis. Oncogene. 2003 Oct 30; 22(49):7831-7.
    View in: PubMed
    Score: 0.160
  20. Activities of wildtype and mutant p53 in suppression of homologous recombination as measured by a retroviral vector system. Mutat Res. 2003 Jan 28; 522(1-2):69-83.
    View in: PubMed
    Score: 0.152
  21. Does p53 affect organismal aging? J Cell Physiol. 2002 Jul; 192(1):23-33.
    View in: PubMed
    Score: 0.146
  22. p53 mutant mice that display early ageing-associated phenotypes. Nature. 2002 Jan 03; 415(6867):45-53.
    View in: PubMed
    Score: 0.141
  23. Differential gene expression in mouse mammary adenocarcinomas in the presence and absence of wild type p53. Oncogene. 2000 Dec 07; 19(52):5988-96.
    View in: PubMed
    Score: 0.131
  24. The structure and expression of the murine wildtype p53-induced phosphatase 1 (Wip1) gene. Genomics. 2000 Mar 15; 64(3):298-306.
    View in: PubMed
    Score: 0.124
  25. p53 in embryonic development: maintaining a fine balance. Cell Mol Life Sci. 1999 Jan; 55(1):38-47.
    View in: PubMed
    Score: 0.114
  26. Literature-based automated discovery of tumor suppressor p53 phosphorylation and inhibition by NEK2. Proc Natl Acad Sci U S A. 2018 10 16; 115(42):10666-10671.
    View in: PubMed
    Score: 0.112
  27. Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice. Cancer Res. 2017 03 15; 77(6):1250-1260.
    View in: PubMed
    Score: 0.101
  28. The role of p53 loss in genomic instability and tumor progression in a murine mammary cancer model. Prog Clin Biol Res. 1996; 395:1-11.
    View in: PubMed
    Score: 0.093
  29. Coamplification of Myc/Pvt1 and homozygous deletion of Nlrp1 locus are frequent genetics changes in mouse osteosarcoma. Genes Chromosomes Cancer. 2015 Dec; 54(12):796-808.
    View in: PubMed
    Score: 0.091
  30. Effects of genetic background on tumorigenesis in p53-deficient mice. Mol Carcinog. 1995 Sep; 14(1):16-22.
    View in: PubMed
    Score: 0.091
  31. Ghrelin Prevents Cisplatin-Induced Testicular Damage by Facilitating Repair of DNA Double Strand Breaks Through Activation of p53 in Mice. Biol Reprod. 2015 Jul; 93(1):24.
    View in: PubMed
    Score: 0.089
  32. Deficiency of p53 accelerates mammary tumorigenesis in Wnt-1 transgenic mice and promotes chromosomal instability. Genes Dev. 1995 Apr 01; 9(7):882-95.
    View in: PubMed
    Score: 0.088
  33. In vitro growth characteristics of embryo fibroblasts isolated from p53-deficient mice. Oncogene. 1993 Sep; 8(9):2457-67.
    View in: PubMed
    Score: 0.079
  34. The tumor suppressor p53. Biochim Biophys Acta. 1993 Aug 23; 1155(2):181-205.
    View in: PubMed
    Score: 0.079
  35. Transcriptional and translational regulation of C/EBP?-HDAC1 protein complexes controls different levels of p53, SIRT1, and PGC1a proteins at the early and late stages of liver cancer. J Biol Chem. 2013 May 17; 288(20):14451-14462.
    View in: PubMed
    Score: 0.077
  36. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature. 1992 Mar 19; 356(6366):215-21.
    View in: PubMed
    Score: 0.071
  37. Absence of Wip1 partially rescues Atm deficiency phenotypes in mice. Oncogene. 2012 Mar 01; 31(9):1155-65.
    View in: PubMed
    Score: 0.068
  38. Rpl27a mutation in the sooty foot ataxia mouse phenocopies high p53 mouse models. J Pathol. 2011 Aug; 224(4):540-52.
    View in: PubMed
    Score: 0.068
  39. Mdm2-p53 signaling regulates epidermal stem cell senescence and premature aging phenotypes in mouse skin. Dev Biol. 2011 May 01; 353(1):1-9.
    View in: PubMed
    Score: 0.066
  40. P53 genotype as a determinant of ER expression and tamoxifen response in the MMTV-Wnt-1 model of mammary carcinogenesis. Breast Cancer Res Treat. 2011 Nov; 130(2):399-408.
    View in: PubMed
    Score: 0.066
  41. Dual-specificity phosphatase 26 is a novel p53 phosphatase and inhibits p53 tumor suppressor functions in human neuroblastoma. Oncogene. 2010 Sep 02; 29(35):4938-46.
    View in: PubMed
    Score: 0.063
  42. Augmented cancer resistance and DNA damage response phenotypes in PPM1D null mice. Mol Carcinog. 2006 Aug; 45(8):594-604.
    View in: PubMed
    Score: 0.048
  43. Oxidative and nitrative stress caused by subcutaneous implantation of a foreign body accelerates sarcoma development in Trp53+/- mice. Carcinogenesis. 2007 Jan; 28(1):191-8.
    View in: PubMed
    Score: 0.048
  44. Organ-specific susceptibility of p53 knockout mice to N-bis(2-hydroxypropyl)nitrosamine carcinogenesis. Cancer Lett. 2006 Jul 18; 238(2):271-83.
    View in: PubMed
    Score: 0.046
  45. Reversal of the ATM/ATR-mediated DNA damage response by the oncogenic phosphatase PPM1D. Cell Cycle. 2005 Aug; 4(8):1060-4.
    View in: PubMed
    Score: 0.045
  46. Lack of elevated liver carcinogenicity of aminophenylnorharman in p53-deficient mice. Cancer Lett. 2005 Jan 20; 217(2):149-59.
    View in: PubMed
    Score: 0.043
  47. Diet-gene interactions in p53-deficient mice: insulin-like growth factor-1 as a mechanistic target. J Nutr. 2004 Sep; 134(9):2482S-2486S.
    View in: PubMed
    Score: 0.042
  48. Loss of heterozygosity occurs via mitotic recombination in Trp53+/- mice and associates with mammary tumor susceptibility of the BALB/c strain. Cancer Res. 2004 Aug 01; 64(15):5140-7.
    View in: PubMed
    Score: 0.042
  49. Insights into aging obtained from p53 mutant mouse models. Ann N Y Acad Sci. 2004 Jun; 1019:171-7.
    View in: PubMed
    Score: 0.042
  50. Transgenic tumor models for carcinogen identification: the heterozygous Trp53-deficient and RasH2 mouse lines. Mutat Res. 2003 Oct 07; 540(2):165-76.
    View in: PubMed
    Score: 0.040
  51. Generation and characterization of p53 mutant mice. Methods Mol Biol. 2003; 234:29-49.
    View in: PubMed
    Score: 0.038
  52. Elevated susceptibility of the p53 knockout mouse esophagus to methyl-N-amylnitrosamine carcinogenesis. Carcinogenesis. 2002 Sep; 23(9):1541-7.
    View in: PubMed
    Score: 0.037
  53. K-Ras and p53 mouse model with molecular characteristics of human rhabdomyosarcoma and translational applications. Dis Model Mech. 2022 02 01; 15(2).
    View in: PubMed
    Score: 0.035
  54. Cancer prevention studies in p53-deficient mice. Toxicol Pathol. 2001 Jan-Feb; 29(1):137-41.
    View in: PubMed
    Score: 0.033
  55. Absence of p53: no effect in a transgenic mouse model of familial amyotrophic lateral sclerosis. Exp Neurol. 2000 Sep; 165(1):184-90.
    View in: PubMed
    Score: 0.032
  56. Synergistic induction of centrosome hyperamplification by loss of p53 and cyclin E overexpression. Oncogene. 2000 Mar 23; 19(13):1635-46.
    View in: PubMed
    Score: 0.031
  57. Mouse models in tumor suppression. Oncogene. 1998 Dec 24; 17(25):3385-400.
    View in: PubMed
    Score: 0.029
  58. Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation. EMBO J. 1998 Aug 17; 17(16):4657-67.
    View in: PubMed
    Score: 0.028
  59. The tumorigenic potential and cell growth characteristics of p53-deficient cells are equivalent in the presence or absence of Mdm2. Proc Natl Acad Sci U S A. 1996 Nov 26; 93(24):14106-11.
    View in: PubMed
    Score: 0.025
  60. Moloney murine leukemia virus-induced lymphomas in p53-deficient mice: overlapping pathways in tumor development? J Virol. 1996 Apr; 70(4):2095-100.
    View in: PubMed
    Score: 0.024
  61. p53 is required for both radiation-induced differentiation and rescue of V(D)J rearrangement in scid mouse thymocytes. Genes Dev. 1996 Mar 01; 10(5):553-65.
    View in: PubMed
    Score: 0.023
  62. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature. 1995 Nov 09; 378(6553):206-8.
    View in: PubMed
    Score: 0.023
  63. p53 deficiency does not affect the accumulation of point mutations in a transgene target. Proc Natl Acad Sci U S A. 1995 Aug 29; 92(18):8517-21.
    View in: PubMed
    Score: 0.023
  64. Astrocytes derived from p53-deficient mice provide a multistep in vitro model for development of malignant gliomas. Mol Cell Biol. 1995 Aug; 15(8):4249-59.
    View in: PubMed
    Score: 0.023
  65. Met proto-oncogene product is overexpressed in tumors of p53-deficient mice and tumors of Li-Fraumeni patients. Cancer Res. 1995 May 01; 55(9):1963-70.
    View in: PubMed
    Score: 0.022
  66. WIP1 phosphatase as a potential therapeutic target in neuroblastoma. PLoS One. 2015; 10(2):e0115635.
    View in: PubMed
    Score: 0.022
  67. Evidence that p53 and bcl-2 are regulators of a common cell death pathway important for in vivo lymphomagenesis. Oncogene. 1994 Nov; 9(11):3107-12.
    View in: PubMed
    Score: 0.021
  68. Mice with reduced levels of p53 protein exhibit the testicular giant-cell degenerative syndrome. Proc Natl Acad Sci U S A. 1993 Oct 01; 90(19):9075-9.
    View in: PubMed
    Score: 0.020
  69. REG? deficiency promotes premature aging via the casein kinase 1 pathway. Proc Natl Acad Sci U S A. 2013 Jul 02; 110(27):11005-10.
    View in: PubMed
    Score: 0.019
  70. Medulloblastomas overexpress the p53-inactivating oncogene WIP1/PPM1D. J Neurooncol. 2008 Feb; 86(3):245-56.
    View in: PubMed
    Score: 0.013
  71. Aging hematopoietic stem cells decline in function and exhibit epigenetic dysregulation. PLoS Biol. 2007 Aug; 5(8):e201.
    View in: PubMed
    Score: 0.013
  72. Dual roles for the phosphatase PPM1D in regulating progesterone receptor function. J Biol Chem. 2006 Mar 17; 281(11):7089-101.
    View in: PubMed
    Score: 0.012
  73. p53 knockout mice (-/-) are more susceptible than (+/-) or (+/+) mice to N-methyl-N-nitrosourea stomach carcinogenesis. Carcinogenesis. 2000 Oct; 21(10):1891-7.
    View in: PubMed
    Score: 0.008
  74. Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. Genes Dev. 2000 Jun 15; 14(12):1448-59.
    View in: PubMed
    Score: 0.008
  75. Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis. Proc Natl Acad Sci U S A. 1998 Dec 22; 95(26):15608-12.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.